Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 10/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15771446 | 0.86 | CCNC (0.46) | CYP1A2TDP1KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL30309922 | 0.84 | LCK (0.46) | CYP3A4CYP1A2CYP2D6LCKBTK | |
| SCHEMBL15784053 | 0.84 | LCK (0.46) | CYP3A4CYP1A2CYP2D6LCKBTK | |
| SCHEMBL19721401 | 0.84 | GRM4 (0.49) | GPBAR1NPC1RAB9ASMN1; SMN2MAOA | |
| SCHEMBL17506374 | 0.81 | AOC1 (0.52) | SMN1; SMN2MAOAMAOBCYP3A4CYP1A2 | |
| SCHEMBL12811651 | 0.79 | CYP1A2 (0.51) | MAOAMAOBLIMK1CYP3A4CYP1A2 | |
| SCHEMBL15777719 | 0.78 | ATR (0.42) | GPBAR1NPC1MAOAMAOBCYP3A4 | |
| SCHEMBL30309932 | 0.78 | ATR (0.42) | GPBAR1NPC1MAOAMAOBCYP3A4 | |
| SCHEMBL21647183 | 0.77 | SMARCA2 (0.45) | SMN1; SMN2MAOAMAOBTDP1KDM4E | |
| SCHEMBL6635250 | 0.77 | LIMK1 (0.56) | NPC1RAB9ASMN1; SMN2MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180072735-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2018-03-15 | — | — | US | disclosed |
| US-9650381-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-05-16 | — | — | US | disclosed |
| US-9340546-B2 | Compounds useful as inhibitors of ATR kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2015-06-04 | — | — | US | disclosed |
| CN-101679266-B | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| EP-2681194-B1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8987307-B2 | 3-amino-pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-09-04 | — | — | US | disclosed |
| EP-2132177-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | HOFFMANN-LA ROCHE INC. | 2012-09-13 | — | — | US | disclosed |
| WO-2012117000-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-07 | — | — | WO | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-16 | — | — | US | disclosed |
| CN-101679266-A | PIM kinase inhibitors and methods of their use | NOVARTIS AG | 2010-03-24 | — | — | CN | disclosed |
| EP-2132177-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis Ag (CH) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008106692-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10385022-B2 | 3-amino-pyridines as GPBAR1 agonists | GPBAR1, ADRA1B, GPR119 | GPBAR1 1/4885NPC1 1169/4885RAB9A 2283/4885 |
| US-20120232051-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | GPBAR1 1/4885NPC1 1169/4885RAB9A 2283/4885 |
| US-20140249135-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | GPBAR1 4112/4885NPC1 4325/4885RAB9A 4183/4885 |
| US-20150152058-A1 | 3-AMINO-PYRIDINES AS GPBAR1 AGONISTS | GPBAR1, ADRA1B, GPR119 | GPBAR1 1/4885NPC1 1169/4885RAB9A 2283/4885 |
| US-20120208815-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | GPBAR1 4112/4885NPC1 4325/4885RAB9A 4183/4885 |
| US-20180072735-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, MAP3K20, TBK1 | GPBAR1 4445/4885NPC1 3218/4885RAB9A 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.